Myelodysplastic syndromes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• PD-1 1
• IL-1 2
• NLRP3 1
• NPM1 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• SGLT2 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 687 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Updated 4 Nov 2026

  “FDA Clinical Hold”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

  NCT03150004· Medical College of Wisconsin· Updated 21 Oct 2026

  “No longer have funding support to complete the pharmacogenetics component.”Registry text, quoted unchanged. Source

• Suspended

  Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

  NCT03969446· City of Hope Medical Center· Updated 20 Oct 2026

  “Accrual goal Met”Registry text, quoted unchanged. Source

• Terminated

  MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Updated 20 Oct 2026

  “The trial closed early due to changes in support for the study drug.”Registry text, quoted unchanged. Source

• Suspended

  Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  NCT06454409· City of Hope Medical Center· Updated 20 Oct 2026

  “resources”Registry text, quoted unchanged. Source

• Suspended

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Updated 15 Oct 2026

  “Timeline Adjustment”Registry text, quoted unchanged. Source

• Suspended

  Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

  NCT06630221· Abhay Singh, MD MPH· Updated 9 Oct 2026

  “Funding unavailable”Registry text, quoted unchanged. Source

• Suspended

  Ascorbate in Myelodysplastic Syndrome

  NCT07283900· Prajwal Dhakal· Updated 9 Oct 2026

  “temporary suspension”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

  NCT06597734· M.D. Anderson Cancer Center· Updated 5 Oct 2026

  “PI request”Registry text, quoted unchanged. Source

• Terminated

  Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT06419634· Bristol-Myers Squibb· Updated 1 Oct 2026

  “Inability to meet protocol objectives”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.

  2022-501485-22-00· Celgene Corp.· Source

• Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

  NCT07683104· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  NCT07617363· Washington University School of Medicine· Source

• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· National Cancer Institute (NCI)· Source

• A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Takeda· Source

• A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Takeda· Source

• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS

  2022-500430-29-00· Celgene Corp.· Source

• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  NCT06577441· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

See which targets of this disease your abstract mentions, and go to the people working on them.